UNIVERSITY OF UTAH RESEARCHERS DEVELOP FASTER, MORE ACCURATE TEST FOR LIVER CANCER THAT CAN BE ADMINISTERED ANYWHERE
It’s estimated that about 788,000 people worldwide died of liver cancer in 2015, the second-leading cause of cancer deaths, according to the latest statistics from the World Health Organization. One of the major challenges in combatting this disease is detecting it early because symptoms often don’t appear until later stages.
But a team of researchers led by University of Utah chemical engineering and chemistry professor Marc Porter and U surgeon and professor Courtney Scaife has developed a rapid portable screening test for liver cancer (hepatocellular carcinoma) that doesn’t involve sending a specimen to a blood lab and cuts the wait time for results from two weeks to two minutes. This new and inexpensive test — the team is working to lower the cost to about $3 per test — can be administered wherever the patient is, which will be particularly valuable in developing nations with little access to hospitals.
The test uses a small domino-sized plastic cartridge containing a paper membrane that selectively traps biomarkers (proteins specific to a certain disease) from biological fluids. A small droplet of blood, saliva, or urine, or even a teardrop, from the patient is dropped onto the membrane. This is followed by the droplet of gold nanoparticles, which tags the biomarkers trapped in the membrane. If the biomarkers are present, a red spot appears, signaling the patient has the disease and should seek more testing and possible treatment.
“The concept is similar to a home pregnancy test, but instead of flowing laterally, it flows through the membrane,” says Granger, the lead author on the paper.
A handheld spectrometer manufactured by project collaborator B&W Tek, a Delaware-based manufacturer of mobile spectrometers, can analyze the membranes and measure how much of the biomarkers is present, which in the future could determine the severity of the disease or how a patient is responding to treatment.
The idea for the test is a spinoff of a similar test Porter developed eight years ago that astronauts on the International Space Station used to test the cleanliness of their drinking water. “This is a smarter offshoot of that,” says Porter, who also is the director of the Nano Institute of Utah.
Now that the team has proven the concept with liver cancer and built a prototype test kit, researchers plan to evaluate the technology in Mongolia in spring of 2019. The East Asian country has the highest rate of liver cancer in the world.
The project was funded by grants from the National Institutes of Health, the National Cancer Institute through the Affordable Cancer Technologies Program and the Huntsman Cancer Institute. The team also received funding from Utah-based nutritional supplement company USANA which is interested in using a form of the test for customers with certain vitamin deficiencies.
“USANA has a keen interest in the ability to measure certain vitamins and biomarkers in various bodily fluids that can be related to a person’s health status,” said Mark Brown, Executive Director of Laboratory Sciences at USANA. “This would allow our customers to see for themselves the benefit of taking USANA’s high quality products. Rather than taking a blood sample and sending it off to lab for analysis, this technology could make it possible for people to do their own analysis in the comfort of their own home. Small sample size and simplicity of use are crucial components of making this a reality, and this research is a step closer to that end.”
Learn more: PUTTING IT TO THE TEST
The Latest on: Liver cancer
[google_news title=”” keyword=”liver cancer” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]- Study reveals how gender affects liver transplant success in cancer patientson May 9, 2024 at 10:11 am
Liver transplantation is a life-saving option for those with hepatocellular carcinoma (HCC), the most prevalent type of liver cancer. Although often successful, outcomes can vary widely among ...
- Intermittent fasting protects against liver inflammation, liver cancer: Studyon May 9, 2024 at 5:18 am
Intermittent fasting has been found in multiple studies to be an effective way to lose weight and alleviate some metabolic disorders. Heikenwalder's team has now investigated in mice if this method ...
- Intermittent fasting halts liver disease progression and reduces cancer riskon May 8, 2024 at 11:13 pm
Fatty liver disease often leads to chronic liver inflammation and can even result in liver cancer. Scientists from the German Cancer Research Center (DKFZ) and the University of Tübingen have now ...
- New study reveals how gender affects liver transplant success in cancer patientson May 8, 2024 at 5:00 pm
for hepatocellular carcinoma (HCC), the most common type of liver cancer. The study reveals that female recipients experience significantly better post-transplant outcomes than their male counterparts ...
- Do you know intermittent fasting protects against liver inflammation, liver cancer? Study findson May 7, 2024 at 12:02 pm
Fatty liver disease frequently causes chronic liver inflammation and can possibly result in liver cancer. Scientists at the German Cancer Research Centre (DKFZ) and the University of Tubingen have ...
- Intermittent fasting protects against liver inflammation and liver canceron May 6, 2024 at 4:59 pm
Fatty liver disease often leads to chronic liver inflammation and can even result in liver cancer. Scientists have now shown in mice that intermittent fasting on a 5:2 schedule can halt this ...
- Combo Therapy May Be Advance Against Liver Canceron May 6, 2024 at 3:00 am
A new combination therapy appears to boost the response rate for liver cancer patients receiving immunotherapy, accordin ...
- Novel Blood Biomarkers Show Potential for Early Liver Cancer Diagnosison May 1, 2024 at 5:00 pm
“Liver cancer rates are rapidly increasing, and liver cancer has a high mortality rate, but if we can diagnose it early, therapeutic interventions can be potentially curative,” lead author Xinyuan ...
- Liver Cancer Screening Benefits Patients With Cirrhosis, Study Suggestson May 1, 2024 at 2:01 pm
Among more than 1,300 patients diagnosed with HCC, the median survival reached 37 months for those with screening-detected tumors compared with 19 months for those whose tumors were found incidentally ...
- Researchers identify biomarkers in blood to predict liver canceron April 30, 2024 at 5:00 pm
Early detection has the potential to transform treatment and outcomes in cancer care, especially for cancers like liver cancer, which is typically diagnosed at a late stage with limited options for ...
via Google News and Bing News